Results 101 to 110 of about 272,512 (195)

MYCN Gene Amplification [PDF]

The American Journal of Pathology, 1999
Maisa Yoshimoto, Silvia Regina Caminada de Toledo, Eliana Maria Monteiro Caran, Maria Teresa de Seixas, Maria Lucia de Martino Lee, Simone de Campos Vieira Abib, Sonia Maria Rossi Vianna, Sergio Thomaz Schettini, Joyce Anderson Duffles Andrade   +8 more
openaire   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging

Neoplasia: An International Journal for Oncology Research
Background: In neuroblastoma MYCN amplification is associated with enhanced angiogenesis and poor survival. Mutations in the anaplastic lymphoma kinase (ALK) gene can occur with MYCN amplification, conferring a very poor prognosis.
Gilberto S. Almeida, Philippa King, Albert Hallsworth, Hannah Webber, Sergey Popov, Susana Miranda, Orli Yogev, Andrew D.J. Pearson, Louis Chesler, Yann Jamin, Simon P. Robinson   +10 more
doaj   +1 more source

Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation

Cell Reports, 2017
Growing evidence suggests a major role for Src-homology-2-domain-containing phosphatase 2 (SHP2/PTPN11) in MYCN-driven high-risk neuroblastoma, although biologic confirmation and a plausible mechanism for this contribution are lacking.
Xiaoling Zhang, Zhiwei Dong, Cheng Zhang, Choong Yong Ung, Shuning He, Ting Tao, Andre M. Oliveira, Alexander Meves, Baoan Ji, A. Thomas Look, Hu Li, Benjamin G. Neel, Shizhen Zhu   +12 more
doaj   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source

Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods

Brain Pathology, Volume 36, Issue 5, September 2026.
This study characterizes the molecular subgroup–specific features of a nationwide Japanese cohort comprising 242 medulloblastomas (MBs). Furthermore, we introduce SEE‐6‐CNA, a simple, cost‐effective, and FFPE‐compatible molecular test that is applicable to routine pathology samples and serves as a surrogate for risk stratification in non‐WNT/non‐SHH ...
Kohichi Go, Asako Katsuma, Ema Yoshioka, Tomoko Shofuda, Kohei Fukuoka, Koichi Ichimura, Yuko Matsushita, Yohei Mineharu, Yasuhide Makino, Takeshi Kawauchi, Atsushi Sasaki, Junko Hirato, Takeshi Inoue, Yoshinori Kodama, Masayuki Mano, Daisuke Kanematsu, Noriyuki Kijima, Naoki Kagawa, Dai Keino, Akitake Mukasa, Tomonari Suzuki, Koji Yoshimoto, Daisuke Kuga, Keishi Horiguchi, Shigeru Yamaguchi, Masayuki Kanamori, Kai Yamasaki, Kenichi Ishibashi, Takuya Akai, Masayoshi Yamaoka, Ryuji Ishizaki, Atsufumi Kawamura, Shigeo Ohba, Joji Ishida, Ryo Ando, Junya Fukai, Tomoru Miwa, Masazumi Fujii, Ai Muroi, Kuniaki Saito, Atsuko Harada, Yasuhiko Hayashi, Masahiro Nonaka, Young‐Soo Park, Yusuke Kobayashi, Tadashi Higuchi, Yosuke Miyairi, Kazuhisa Yoshifuji, Noriyoshi Takebe, Soichi Oya, Kosuke Nakajo, Mitsutoshi Nakada, Yoshiteru Nakano, Mizuki Kambara, Koji Adachi, Kazuhiro Tanaka, Hideo Nakamura, Yukihiko Sonoda, Ryuta Saito, Takafumi Wataya, Kazuhiko Kurozumi, Michael D. Taylor, Yoshitaka Narita, Soichiro Shibui, Hajime Arai, Hiroaki Sakamoto, Isao Date, Motoo Nagane, Ryo Nishikawa, Yoshiki Arakawa, Yonehiro Kanemura   +70 more
wiley   +1 more source

MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.

, 1997
PURPOSE To evaluate the prognostic role of MYCN oncogene amplification in children with neuroblastoma. PATIENTS AND METHODS Of 694 children (age, 0 to 15 years) with previously untreated neuroblastoma, 295 (42%) were evaluated at diagnosis for MYCN gene ...
P Perri, G P Tonini, F Casale, A Pession, D Rogers, K Mazzocco, L Cordero di Montezemolo, P Scaruffi, L Boni, G Basso, C Milanaccio, P Bruzzi, N Marchese, C Lo Cunsolo, A Iolascon, B De Bernardi, M Conte   +16 more
core   +1 more source

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures. [PDF]

Nat Commun, 2023
Schoof M, Godbole S, Albert TK, Dottermusch M, Walter C, Ballast A, Qin N, Olivera MB, Göbel C, Neyazi S, Holdhof D, Kresbach C, Peter LS, Epplen GD, Thaden V, Spohn M, Blattner-Johnson M, Modemann F, Mynarek M, Rutkowski S, Sill M, Varghese J, Afflerbach AK, Eckhardt A, Münter D, Verma A, Struve N, Jones DTW, Remke M, Neumann JE, Kerl K, Schüller U.   +31 more
europepmc   +1 more source

Heterogeneity of the MYCN oncogene in neuroblastoma

, 2009
PURPOSE: MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity. EXPERIMENTAL DESIGN:
Christiansen, H, Niggli, F, Hero, B, Boensch, M, Stegmaier, S, Betts, D, Berthold, F, Spitz, R, Theissen, J, Simon, T, Westermann, F, Schwab, M, Schilling, F   +12 more
core   +1 more source